441 results
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
business EPS(1) to remain roughly stable excluding the impact of an expected effective tax rate increase to 21% and decrease low single-digit(2) at CER … including the higher expected tax rate, barring unforeseen major adverse events. Applying average April 2024 exchange rates, the currency impact
F-3ASR
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
at a substantial discount to their stated principal amount. (Section 101) Special U.S. federal income tax, accounting and other considerations may apply … securities so issued will be issued with no more than de minimis original issue discount for U.S. federal income tax purposes or be part
F-3ASR
EX-1.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters …
Pricing date
Expected settlement date
Maturity date
Day count convention
Optional redemption
Tax redemption
Ranking
Interest rate
Benchmark Treasury price
F-3ASR
EX-25.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
in Thousands
RIAD
Amount
1. Interest expense incurred to carry tax-exempt securities, loans, and leases acquired after
August 7, 1986 … , that is not deductible for federal income tax purposes
M.1.
Memorandum item 2 is to be completed by banks with $1 billion or more in total assets (1)
2. Income from
F-3ASR
EX-4.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
. Securities Redeemed in Part.
-iii-
TABLE OF CONTENTS
(continued)
Page
SECTION 1108. Optional Redemption Due to Changes in Tax Treatment.
SECTION … Maturity as permitted under Section 1108 (“Optional Redemption Due to Changes in Tax Treatment”).
In the event of redemption of this Security in part only
6-K
EX-99.2
3ztbhl6d j1
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
EX-99.1
dqzpw04c
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
F-6EF
EX-99
x9ec0n73g9
18 Dec 23
Automatic registration for ADRs (foreign)
5:23pm
F-6EF
EX-99
hamsp
18 Dec 23
Automatic registration for ADRs (foreign)
5:23pm
6-K
EX-99.1
lj9 3snoqa9
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
6-K
EX-99.1
o2b04
27 Oct 23
Sanofi Enters Next Chapter of Play to Win Strategy
11:33am
6-K
EX-99.1
3qvn1u4flhyi
5 Sep 23
Sanofi announces changes to its Executive Committee
6:19am
6-K
EX-99.1
3jh22hx20mza1mt
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
6-K
EX-99.2
vhit8
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.1
gh15ta
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
11-K
s8creq1s7ajjxcj4yo
28 Jun 23
Annual report of employee stock purchases
2:32pm
11-K
atacz rc23orqd5
28 Jun 23
Annual report of employee stock purchases
2:31pm
6-K
EX-99.3
dcd ppz92tmcgdk
2 Jun 23
Approval of the financial statements for the fiscal year 2022
10:53am
6-K
EX-99.1
u31lgut85p0pekvmg
27 Apr 23
Strong Q1 growth driven by Specialty Care, Vaccines and CHC
11:39am
6-K
EX-99.1
ys3xitf4yftk6wjny9
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am